ArticleFrontiers in bioinformatics2025
ParaDeep: sequence-based deep learning for residue-level paratope prediction using chain-aware BiLSTM-CNN models.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating deep learning with physics based modeling enables high precision antibody antigen interface prediction.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of antibody paratopes is a critical challenge in structure-limited, high-throughput discovery workflows. We present ParaDeep, a lightweight and interpretable deep learning framework for residue-level paratope prediction directly from amino acid sequences. ParaDeep integrates bidirectional long short-term memory networks with one-dimensional convolutional layers to capture both long-range sequence context and local binding motifs. We systematically evaluated 30 model configurations varying in encoding schemes, convolutional kernel sizes, and antibody chain types. In five-fold cross-validation, heavy (H) chain models achieved the highest performance (F1 = 0.856 ± 0.014, MCC = 0.842 ± 0.015), outperforming light (L) chain models (F1 = 0.774 ± 0.023, MCC = 0.772 ± 0.022). On an independent blind test set, ParaDeep attained F1 = 0.723 and MCC = 0.685 for H chains, and F1 = 0.607 and MCC = 0.587 for L chains, representing a 27% MCC improvement over the sequence-based baseline Parapred. Chain-specific modeling revealed that heavy chains provide stronger sequence-based predictive signals, while light chains benefit more from structural context. ParaDeep approaches the performance of state-of-the-art structure-based methods on heavy chains while requiring only sequence input, enabling faster and broader applicability without the computational cost of 3D modeling. Its efficiency and scalability make it well-suited for early-stage antibody discovery, repertoire profiling, and therapeutic design, particularly in the absence of structural data. The implementation is freely available at https://github.com/PiyachatU/ParaDeep, with Python (PyTorch) code and a Google Colab interface for ease of use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.